TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 9466166

Group type: EXPERIMENTAL
Intervention: RS-8359
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Moclobemide
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 7930332

Group type: EXPERIMENTAL
Intervention: Physician assessment before psychiatrist's opinion
Number of subjects: 2100

Group type: EXPERIMENTAL
Intervention: Physician assessment after psychiatrist's opinion
Number of subjects: 2100

Group type: EXPERIMENTAL
Intervention: Knowledge of the correct standard for competence
Number of subjects: 2100

Group type: EXPERIMENTAL
Intervention: Responses regarding conditions establishing incompetence
Number of subjects: 2100

Group type: EXPERIMENTAL
Intervention: Performance comparison between psychiatrists and other physicians
Number of subjects: 2100
Study: 3410944

Group type: EXPERIMENTAL
Intervention: Sterile skin preparation technique
Number of subjects: 71

Group type: COMPARATOR
Intervention: Clean technique
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Antibiotics
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Antiseptic application in patients with poor hygiene
Number of subjects: 71
Study: 31944617

Group type: EXPERIMENTAL
Intervention: Intensive intervention
Number of subjects: 549

Group type: COMPARATOR
Intervention: Comparison program
Number of subjects: 549
Study: 29738561

Group type: EXPERIMENTAL
Intervention: High-dose (HD) amoxicillin/clavulanate 1750 mg IR twice a day (Period 2)
Number of subjects: 315

Group type: COMPARATOR
Intervention: Standard-dose (SD) amoxicillin/clavulanate 875/125 mg IR
Number of subjects: 315

Group type: EXPERIMENTAL
Intervention: High-dose (HD) amoxicillin/clavulanate 2000 mg ER (Period 1)
Number of subjects: 315

Group type: EXPERIMENTAL
Intervention: High-dose (HD) amoxicillin/clavulanate
Number of subjects: 315

Group type: COMPARATOR
Intervention: Standard-dose (SD) amoxicillin/clavulanate
Number of subjects: 315
Study: 26789984

Group type: EXPERIMENTAL
Intervention: Endobronchial valve (EBV) therapy
Number of subjects: 492

Group type: COMPARATOR
Intervention: Control therapy
Number of subjects: 492
Study: 26215478

Group type: EXPERIMENTAL
Intervention: ASK intervention model (300 min/week of physical activity/PE)
Number of subjects: 1145

Group type: COMPARATOR
Intervention: Curriculum-prescribed physical activity intervention (135 min/week)
Number of subjects: 1145
Study: 23979267

Group type: EXPERIMENTAL
Intervention: modified whole blood (mWB)
Number of subjects: 107

Group type: COMPARATOR
Intervention: component therapy (COMP)
Number of subjects: 107
Study: 21092076

Group type: EXPERIMENTAL
Intervention: docetaxel/carboplatin (DC)
Number of subjects: 0

Group type: COMPARATOR
Intervention: docetaxel single-agent (D)
Number of subjects: 0
Study: 19138237

Group type: EXPERIMENTAL
Intervention: Inhaled steroid withdrawal for 12 weeks
Number of subjects: 27

Group type: COMPARATOR
Intervention: Inhaled steroid treatment (before withdrawal)
Number of subjects: 27
Study: 16103032

Group type: EXPERIMENTAL
Intervention: Acute care including a 24 hour crisis resolution team
Number of subjects: 260

Group type: COMPARATOR
Intervention: Standard care from inpatient services and community mental health teams
Number of subjects: 260
Study: 12113325

Group type: EXPERIMENTAL
Intervention: 1 mL 25% sucrose given orally 2 min before heel prick
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Milk intake by nasogastric tube once during the last hour before heel prick
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Milk intake by nasogastric tube and 1 mL 25% sucrose given orally 2 min before heel prick
Number of subjects: 12

Group type: COMPARATOR
Intervention: Sterilized water
Number of subjects: 12
Study: 10344466

Group type: EXPERIMENTAL
Intervention: Polymyxin B-immobilized fiber (PMX-F) treatment
Number of subjects: 30

Group type: COMPARATOR
Intervention: Conventional therapies
Number of subjects: 30
Study: 8964127

Group type: EXPERIMENTAL
Intervention: Bradykinin
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Angiotensin-converting enzyme gene polymorphism
Number of subjects: 105
Study: 1749827

Group type: EXPERIMENTAL
Intervention: Oral scopolamine (1.2 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Clonidine (0.2 mg)
Number of subjects: 0
Study: 6762044

Group type: EXPERIMENTAL
Intervention: 3% acyclovir (ACV) eye ointment
Number of subjects: 38

Group type: COMPARATOR
Intervention: 0.5% idoxiuridine (IDU)
Number of subjects: 38
Study: 30965064

Group type: EXPERIMENTAL
Intervention: OTX-101 0.09%
Number of subjects: 744

Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 744
Study: 29795005

Group type: EXPERIMENTAL
Intervention: HFCS-sweetened beverage
Number of subjects: 41

Group type: COMPARATOR
Intervention: Control beverage (artificially sweetened)
Number of subjects: 41
Study: 26844543

Group type: EXPERIMENTAL
Intervention: Breastfeeding for 12 months or longer
Number of subjects: 323

Group type: EXPERIMENTAL
Intervention: Exclusive breastfeeding duration
Number of subjects: 323

Group type: EXPERIMENTAL
Intervention: Duration of breastfeeding
Number of subjects: 323

Group type: EXPERIMENTAL
Intervention: Exclusive breastfeeding
Number of subjects: 323
Study: 24768443

Group type: EXPERIMENTAL
Intervention: Axillary dissection (AD)
Number of subjects: 238

Group type: COMPARATOR
Intervention: No axillary dissection (no AD)
Number of subjects: 238

Group type: EXPERIMENTAL
Intervention: Conservative surgery with postoperative radiotherapy and tamoxifen for five years
Number of subjects: 238
Study: 22383085

Group type: EXPERIMENTAL
Intervention: Esmolol (bolus of 0.5 mg·kg(‐1) iv at induction followed by infusion of 5‐15 μg·kg(‐1)·min(‐1))
Number of subjects: 60

Group type: COMPARATOR
Intervention: Remifentanil plus ketamine (bolus of ketamine 0.5 mg·kg(‐1) iv and remifentanil 0.5 μg·kg(‐1) iv at induction followed by a remifentanil infusion titrated over a range of 0.1‐0.5 μg·kg(‐1)·min(‐1))
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Esmolol
Number of subjects: 60

Group type: COMPARATOR
Intervention: Remifentanil plus ketamine
Number of subjects: 60
Study: 19403955

Group type: EXPERIMENTAL
Intervention: CCP (6 g/d CLA + 9 g/d C + 36 g/d P)
Number of subjects: 69

Group type: COMPARATOR
Intervention: CP (C + P + placebo oil)
Number of subjects: 69

Group type: COMPARATOR
Intervention: P (P + placebo oil)
Number of subjects: 69

Group type: COMPARATOR
Intervention: All groups
Number of subjects: 69
Study: 16426124

Group type: COMPARATOR
Intervention: Diclofenac (100 mg/daily) plus aescin (80 mg/daily)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Diclofenac (100 mg/daily) plus aescin (80 mg/daily) plus tamsulosin (0.4 mg/daily)
Number of subjects: 96
Study: 12569556

Group type: EXPERIMENTAL
Intervention: Mucosal IgA response
Number of subjects: 627

Group type: EXPERIMENTAL
Intervention: Mucosal IgG response
Number of subjects: 627

Group type: EXPERIMENTAL
Intervention: IgA response
Number of subjects: 627

Group type: EXPERIMENTAL
Intervention: IgG response
Number of subjects: 627
Study: 10976549

Group type: EXPERIMENTAL
Intervention: 20 mg temazepam
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study: 8787684

Group type: EXPERIMENTAL
Intervention: Oltipraz 125 mg/m2
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Oltipraz 250 mg/m2
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Oltipraz 500 mg/m2
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Oltipraz 1000 mg/m2
Number of subjects: 24
Study: 1485740

Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen therapy and pharmacologic therapy for 12 patients
Number of subjects: 33

Group type: COMPARATOR
Intervention: Pharmacologic therapy alone for 21 patients
Number of subjects: 33
Study: 6507339

Group type: EXPERIMENTAL
Intervention: Diet providing 20% of energy from protein
Number of subjects: 12

Group type: COMPARATOR
Intervention: Diet providing 10% of energy from protein
Number of subjects: 12
Study: 30762310

Group type: EXPERIMENTAL
Intervention: Epi-off crosslinking (CXL) procedure
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Iatrogenic corneal injury model in rabbits
Number of subjects: 60
Study: 28682186

Group type: EXPERIMENTAL
Intervention: Health-promotion intervention targeting physical activity and dietary habits (fruit, vegetable, and fat consumption)
Number of subjects: 176

Group type: EXPERIMENTAL
Intervention: Health-promotion intervention
Number of subjects: 176
Study: 27458945

Group type: EXPERIMENTAL
Intervention: SRS alone
Number of subjects: 213

Group type: COMPARATOR
Intervention: SRS plus WBRT
Number of subjects: 213
Study: 25559834

Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 40

Group type: COMPARATOR
Intervention: Propofol
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 40
Study: 22763666

Group type: EXPERIMENTAL
Intervention: Intranasally administered oxytocin
Number of subjects: 57

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 57
Study: 20007948

Group type: EXPERIMENTAL
Intervention: Real-time continuous glucose monitoring (CGM)
Number of subjects: 124

Group type: COMPARATOR
Intervention: Control group (selective arterial glucose measurements)
Number of subjects: 124
Study: 17387356

Group type: EXPERIMENTAL
Intervention: Evidence-based medicine (EBM) principles and methods
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Interventional techniques
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Guidelines in interventional pain management
Number of subjects: 0
Study: 16195625

Group type: EXPERIMENTAL
Intervention: Valsartan added to conventional treatment (V group)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Conventional therapy (C group)
Number of subjects: 23
Study: 12269709

Group type: EXPERIMENTAL
Intervention: Structured training for pharmacists to provide individualized asthma management services for up to 1 year.
Number of subjects: 330

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 330
Study: 10415251

Group type: EXPERIMENTAL
Intervention: Magnesium sulphate
Number of subjects: 76

Group type: COMPARATOR
Intervention: Sodium sulphate
Number of subjects: 76
Study: 7556834

Group type: EXPERIMENTAL
Intervention: 0.3% chlorhexidine gel
Number of subjects: 981

Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 981

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 981

Group type: COMPARATOR
Intervention: Chlorhexidine gel vs combined placebo plus control group
Number of subjects: 981
Study: 2288318

Group type: EXPERIMENTAL
Intervention: Pitressin (6 or 10 units) administered by subcutaneous injection 30 minutes prior to contrast medium injection
Number of subjects: 60

Group type: COMPARATOR
Intervention: Routine procedure (laxatives the previous night and NPO the morning of the examination)
Number of subjects: 60
Study: 7420549

Group type: EXPERIMENTAL
Intervention: Adjuvant radiotherapy (4,500R in 28 to 32 days)
Number of subjects: 475

Group type: COMPARATOR
Intervention: Control group (no radiotherapy)
Number of subjects: 475
Study: 31006142

Group type: EXPERIMENTAL
Intervention: Laser-assisted hair removal treatment by trained nurses
Number of subjects: 94
Study: 28279480

Group type: EXPERIMENTAL
Intervention: Initial treatment
Number of subjects: 395

Group type: EXPERIMENTAL
Intervention: Low level smokers
Number of subjects: 395

Group type: EXPERIMENTAL
Intervention: Low and moderate level alcohol drinkers
Number of subjects: 395

Group type: EXPERIMENTAL
Intervention: Endometrial cancer patients
Number of subjects: 395

Group type: EXPERIMENTAL
Intervention: Ovarian cancer patients
Number of subjects: 395

Group type: EXPERIMENTAL
Intervention: Patients with lower trust in treatment
Number of subjects: 395
Study: 26184850

Group type: EXPERIMENTAL
Intervention: Intensified follow-up protocol with CEA measurements every two months and imaging in case of two CEA rises
Number of subjects: 3223

Group type: EXPERIMENTAL
Intervention: Intensified follow-up protocol
Number of subjects: 3223
Study: 23991829

Group type: EXPERIMENTAL
Intervention: Aprepitant 80 mg
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Aprepitant 125 mg
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 21866658

Group type: EXPERIMENTAL
Intervention: Danshen Chuanxiongqin Injection (DCI) 10 mL intravenously dripped in 250 mL normal saline, once daily for 7 to 10 days before PCI
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Danshen Chuanxiongqin Injection (DCI)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Routine treatment of Western medicine and PCI (Control group)
Number of subjects: 76
Study: 19512973

Group type: COMPARATOR
Intervention: Acute ketamine administration (low dose: 75 ng/mL; high dose: 150 ng/mL)
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Regular recreational ketamine users
Number of subjects: 86

Group type: COMPARATOR
Intervention: Ketamine-naive polydrug controls
Number of subjects: 86

Group type: COMPARATOR
Intervention: Non-drug-using controls
Number of subjects: 86
Study: 16624928

Group type: EXPERIMENTAL
Intervention: Infliximab (a monoclonal antibody to TNF)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Etanercept (a soluble TNF receptor fusion protein)
Number of subjects: 0
Study: 12632029

Group type: EXPERIMENTAL
Intervention: Kawasaki disease patients
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Kawasaki disease patients with coronary aneurysms
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Kawasaki disease patients without coronary lesions
Number of subjects: 42

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 42
Study: 10694615

Group type: EXPERIMENTAL
Intervention: Coronary bypass plus transmyocardial revascularization (n = 132)
Number of subjects: 263

Group type: COMPARATOR
Intervention: Coronary bypass alone (n = 131)
Number of subjects: 263
Study: 9166316

Group type: EXPERIMENTAL
Intervention: Continuous vacuum extraction (600 mmHg maintained until delivery)
Number of subjects: 322

Group type: COMPARATOR
Intervention: Intermittent vacuum extraction (100 mmHg between contractions)
Number of subjects: 322

Group type: EXPERIMENTAL
Intervention: Continuous vacuum extraction
Number of subjects: 322

Group type: COMPARATOR
Intervention: Intermittent vacuum extraction
Number of subjects: 322

Group type: EXPERIMENTAL
Intervention: Both methods
Number of subjects: 322
Study: 8268901

Group type: EXPERIMENTAL
Intervention: Active treatment (antihypertensive treatment)
Number of subjects: 12483

Group type: COMPARATOR
Intervention: Control group (no active treatment)
Number of subjects: 12483
Study: 4037442

Group type: EXPERIMENTAL
Intervention: Glucose + 100 mg X kg‐1 X d‐1 of ketoleucine (Group B)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Glucose + 200 mg X kg‐1 X d‐1 of ketoleucine (Group C)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Glucose (Group A)
Number of subjects: 29
Study: 31606036

Group type: EXPERIMENTAL
Intervention: Tailored intervention and implementation plan with coaching support
Number of subjects: 600

Group type: COMPARATOR
Intervention: Deferred intervention group
Number of subjects: 600
Study: 28444716

Group type: EXPERIMENTAL
Intervention: Soft-chew formulation (100 mg ibuprofen)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Hard tablet (reference, 100 mg ibuprofen)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Soft-chew formulation (3 chews)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Soft-chew formulation (8 chews)
Number of subjects: 0
Study: 27246676

Group type: EXPERIMENTAL
Intervention: Michigan Model for Health (MMH) intervention
Number of subjects: 1983

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 1983
Study: 24762458

Group type: EXPERIMENTAL
Intervention: Training through an online podcast
Number of subjects: 100

Group type: COMPARATOR
Intervention: Training through a synopsis
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Both training methods (podcast and synopsis)
Number of subjects: 100
Study: 22802437

Group type: EXPERIMENTAL
Intervention: Hygiene promotion and water treatment intervention
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Addition of new latrines to intervention schools
Number of subjects: 0
Study: 19729583

Group type: EXPERIMENTAL
Intervention: Bilateral Arm Training (BAT) for 2 hours on weekdays for 3 weeks
Number of subjects: 33

Group type: COMPARATOR
Intervention: Control Intervention (CI) for 2 hours on weekdays for 3 weeks
Number of subjects: 33
Study: 17851995

Group type: EXPERIMENTAL
Intervention: HIV prevention interventions targeting adolescents in and out of school
Number of subjects: 246

Group type: EXPERIMENTAL
Intervention: Multi-component approach to prevention including programmes based in schools, communities, mass media, and health facilities
Number of subjects: 246
Study: 16213034

Group type: EXPERIMENTAL
Intervention: Stimulant medication in ADHD/C subjects
Number of subjects: 0

Group type: COMPARATOR
Intervention: ADHD/C subjects
Number of subjects: 0

Group type: COMPARATOR
Intervention: ADHD/I subjects
Number of subjects: 0

Group type: COMPARATOR
Intervention: Controls
Number of subjects: 0
Study: 12371916

Group type: EXPERIMENTAL
Intervention: Sodium valproate
Number of subjects: 52

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study: 12559061

Group type: EXPERIMENTAL
Intervention: 10 weekly group sessions emphasizing food label information
Number of subjects: 92
Study: 9581027

Group type: EXPERIMENTAL
Intervention: meso‐2,3‐dimercaptosuccinic acid (DMSA) at a dose of 30 mg kg‐1
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: D,L‐2,3‐dimercaptopropane‐1‐sulfonic acid (DMPS) at a dose of 30 mg kg‐1
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control (urines)
Number of subjects: 12
Study: 8068949

Group type: EXPERIMENTAL
Intervention: Chemotherapy arm (T-ALL patients: 26, B-ALL patients: 57)
Number of subjects: 562

Group type: EXPERIMENTAL
Intervention: Autologous bone marrow transplantation (ABMT) arm (T-ALL patients: 35, B-ALL patients: 50)
Number of subjects: 562

Group type: EXPERIMENTAL
Intervention: Allogeneic bone marrow transplantation (alloBMT) arm (T-ALL patients: 37, B-ALL patients: 71)
Number of subjects: 562

Group type: EXPERIMENTAL
Intervention: CD10+ T-ALL (31 patients)
Number of subjects: 562

Group type: EXPERIMENTAL
Intervention: T-cell leukemia
Number of subjects: 562
Study: 3054619

Group type: EXPERIMENTAL
Intervention: Nimodipine
Number of subjects: 127

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 127
Study: 29641294

Group type: EXPERIMENTAL
Intervention: Adaptive Servoventilation (ASV)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Supplemental Oxygen
Number of subjects: 18

Group type: COMPARATOR
Intervention: No Treatment
Number of subjects: 18
Study: 28848332

Group type: EXPERIMENTAL
Intervention: CGA unit treatment
Number of subjects: 408

Group type: COMPARATOR
Intervention: Conventional acute medical care unit
Number of subjects: 408
Study: 25168034

Group type: EXPERIMENTAL
Intervention: Lozenge + Coach Calls (n = 357)
Number of subjects: 1067

Group type: COMPARATOR
Intervention: Lozenge (n = 356)
Number of subjects: 1067

Group type: COMPARATOR
Intervention: Coach Calls (n = 354)
Number of subjects: 1067
Study: 23299909

Group type: EXPERIMENTAL
Intervention: Intermittent ART
Number of subjects: 202

Group type: COMPARATOR
Intervention: Continuous ART
Number of subjects: 202
Study: 21673719

Group type: EXPERIMENTAL
Intervention: Maternal multiple micronutrient supplementation (MMN)
Number of subjects: 14293

Group type: COMPARATOR
Intervention: Iron/folic acid supplementation
Number of subjects: 14293
Study: 18394129

Group type: EXPERIMENTAL
Intervention: Asthma Quality-of-life Questionnaire (AQLQ)
Number of subjects: 900

Group type: EXPERIMENTAL
Intervention: Short Form-36 (SF-36)
Number of subjects: 900

Group type: EXPERIMENTAL
Intervention: Asthma attack frequency and hospitalization
Number of subjects: 900

Group type: EXPERIMENTAL
Intervention: Nocturnal symptoms and lung function
Number of subjects: 900
Study: 17145534

Group type: EXPERIMENTAL
Intervention: High-dose three-dimensional conformal radiotherapy (3DCRT) at 66 Gy, 2 Gy/fraction
Number of subjects: 27
Study: 14505088

Group type: EXPERIMENTAL
Intervention: Penciclovir (intravenous formulation)
Number of subjects: 1201

Group type: EXPERIMENTAL
Intervention: Topical penciclovir
Number of subjects: 1201

Group type: EXPERIMENTAL
Intervention: Oral famciclovir
Number of subjects: 1201

Group type: COMPARATOR
Intervention: Penciclovir
Number of subjects: 1201

Group type: COMPARATOR
Intervention: Aciclovir
Number of subjects: 1201
Study: 11093052

Group type: EXPERIMENTAL
Intervention: Cisplatin and carboplatin (PP group)
Number of subjects: 189

Group type: COMPARATOR
Intervention: Cisplatin, vinblastine and bleomycin (PVB group)
Number of subjects: 189
Study: 9371351

Group type: EXPERIMENTAL
Intervention: Moderate-dose trimethoprim (10 mg/kg/day)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: High-dose trimethoprim (20 mg/kg/day)
Number of subjects: 20
Study: 1583277

Group type: EXPERIMENTAL
Intervention: Test lens pair (corrected all residual astigmatism)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control lens pair (+0.12 DS, considered a placebo)
Number of subjects: 12
Study: 31218913

Group type: EXPERIMENTAL
Intervention: Neurofeedback training
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Physical activity
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control
Number of subjects: 45
Study: 30616699

Group type: EXPERIMENTAL
Intervention: Mometasone furoate aqueous nasal spray (Nasonex) 100 mcg/day for four weeks
Number of subjects: 26

Group type: COMPARATOR
Intervention: Nasal normal saline 0.9 per cent for four weeks
Number of subjects: 26
Study: 27978426

Group type: EXPERIMENTAL
Intervention: Gamified PNF intervention (CampusGANDR)
Number of subjects: 237

Group type: COMPARATOR
Intervention: Standard PNF intervention (control)
Number of subjects: 237
Study: 26328908

Group type: EXPERIMENTAL
Intervention: Cocaine (300 mg)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 23299370

Group type: EXPERIMENTAL
Intervention: Lifestyle intervention
Number of subjects: 16
Study: 21426558

Group type: EXPERIMENTAL
Intervention: Chiropractic spinal manipulative therapy (SMT) plus home exercise program (HEP)
Number of subjects: 192

Group type: COMPARATOR
Intervention: Home exercise program (HEP) alone
Number of subjects: 192
Study: 18957933

Group type: EXPERIMENTAL
Intervention: Lifestyle intervention group
Number of subjects: 522

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 522
Study: 16454480

Group type: EXPERIMENTAL
Intervention: Retirement with freedom from grandchild care obligations
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Continued employment while providing grandchild care
Number of subjects: 0

Group type: COMPARATOR
Intervention: Grandchild care obligations
Number of subjects: 0
Study: 14742346

Group type: EXPERIMENTAL
Intervention: Cognitive behaviour therapy website (MoodGYM)
Number of subjects: 525

Group type: EXPERIMENTAL
Intervention: Psychoeducation website (BluePages)
Number of subjects: 525

Group type: COMPARATOR
Intervention: Control intervention (attention placebo)
Number of subjects: 525